231 related articles for article (PubMed ID: 25175729)
1. Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398.
Grammen C; Van den Mooter G; Appeltans B; Michiels J; Crucitti T; Ariën KK; Augustyns K; Augustijns P; Brouwers J
Int J Pharm; 2014 Nov; 475(1-2):238-44. PubMed ID: 25175729
[TBL] [Abstract][Full Text] [Related]
2. Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1.
Grammen C; Ariën KK; Venkatraj M; Joossens J; Van der Veken P; Heeres J; Lewi PJ; Haenen S; Augustyns K; Vanham G; Augustijns P; Brouwers J
Antiviral Res; 2014 Jan; 101():113-21. PubMed ID: 24269474
[TBL] [Abstract][Full Text] [Related]
3. The use of supersaturation for the vaginal application of microbicides: a case study with dapivirine.
Grammen C; Plum J; Van Den Brande J; Darville N; Augustyns K; Augustijns P; Brouwers J
J Pharm Sci; 2014 Nov; 103(11):3696-3703. PubMed ID: 25231545
[TBL] [Abstract][Full Text] [Related]
4. Development of a vaginal delivery film containing EFdA, a novel anti-HIV nucleoside reverse transcriptase inhibitor.
Zhang W; Parniak MA; Sarafianos SG; Cost MR; Rohan LC
Int J Pharm; 2014 Jan; 461(1-2):203-13. PubMed ID: 24333452
[TBL] [Abstract][Full Text] [Related]
5. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets.
Garg S; Goldman D; Krumme M; Rohan LC; Smoot S; Friend DR
Antiviral Res; 2010 Dec; 88 Suppl 1():S19-29. PubMed ID: 21109064
[TBL] [Abstract][Full Text] [Related]
6. Mucosal toxicity studies of a gel formulation of native pokeweed antiviral protein.
D'Cruz OJ; Waurzyniak B; Uckun FM
Toxicol Pathol; 2004; 32(2):212-21. PubMed ID: 15200159
[TBL] [Abstract][Full Text] [Related]
7. Early identification of availability issues for poorly water-soluble microbicide candidates in biorelevant media: a case study with saquinavir.
Brouwers J; Vermeire K; Grammen C; Schols D; Augustijns P
Antiviral Res; 2011 Aug; 91(2):217-23. PubMed ID: 21683096
[TBL] [Abstract][Full Text] [Related]
8. Vaginal Microbicide Film Combinations of Two Reverse Transcriptase Inhibitors, EFdA and CSIC, for the Prevention of HIV-1 Sexual Transmission.
Zhang W; Hu M; Shi Y; Gong T; Dezzutti CS; Moncla B; Sarafianos SG; Parniak MA; Rohan LC
Pharm Res; 2015 Sep; 32(9):2960-72. PubMed ID: 25794967
[TBL] [Abstract][Full Text] [Related]
9. Recent advances on anti-HIV vaginal delivery systems development.
Antimisiaris SG; Mourtas S
Adv Drug Deliv Rev; 2015 Sep; 92():123-45. PubMed ID: 25858666
[TBL] [Abstract][Full Text] [Related]
10. Development of mucoadhesive vaginal films based on HPMC and zein as novel formulations to prevent sexual transmission of HIV.
Notario-Pérez F; Martín-Illana A; Cazorla-Luna R; Ruiz-Caro R; Bedoya LM; Peña J; Veiga MD
Int J Pharm; 2019 Oct; 570():118643. PubMed ID: 31446023
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent.
Garg S; Vermani K; Garg A; Anderson RA; Rencher WB; Zaneveld LJ
Pharm Res; 2005 Apr; 22(4):584-95. PubMed ID: 15846466
[TBL] [Abstract][Full Text] [Related]
12. Vaginal gel formulation based on theaflavin derivatives as a microbicide to prevent HIV sexual transmission.
Yang J; Li L; Jin H; Tan S; Qiu J; Yang L; Ding Y; Jiang ZH; Jiang S; Liu S
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1498-508. PubMed ID: 22867271
[TBL] [Abstract][Full Text] [Related]
13. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.
Whaley KJ; Hanes J; Shattock R; Cone RA; Friend DR
Antiviral Res; 2010 Dec; 88 Suppl 1():S55-66. PubMed ID: 21109069
[TBL] [Abstract][Full Text] [Related]
14. Vaginal film for prevention of HIV: using visual and tactile evaluations among potential users to inform product design.
Guthrie KM; Rohan L; Rosen RK; Vargas SE; Shaw JG; Katz D; Kojic EM; Ham AS; Friend D; Buckheit KW; Buckheit RW
Pharm Dev Technol; 2018 Mar; 23(3):311-314. PubMed ID: 28592183
[TBL] [Abstract][Full Text] [Related]
15. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo.
Trifonova RT; Pasicznyk JM; Fichorova RN
Antimicrob Agents Chemother; 2006 Dec; 50(12):4005-10. PubMed ID: 17030562
[TBL] [Abstract][Full Text] [Related]
16. Design and in vitro evaluation of tenofovir-loaded vaginal gels for the prevention of HIV infections.
Timur SS; Şahin A; Aytekin E; Öztürk N; Polat KH; Tezel N; Gürsoy RN; Çalış S
Pharm Dev Technol; 2018 Mar; 23(3):301-310. PubMed ID: 28503983
[TBL] [Abstract][Full Text] [Related]
17. In vitro profiling of the vaginal permeation potential of anti-HIV microbicides and the influence of formulation excipients.
Grammen C; Augustijns P; Brouwers J
Antiviral Res; 2012 Nov; 96(2):226-33. PubMed ID: 23000496
[TBL] [Abstract][Full Text] [Related]
18. Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy.
Woodsong C; Holt JD
Adv Drug Deliv Rev; 2015 Sep; 92():146-54. PubMed ID: 25703190
[TBL] [Abstract][Full Text] [Related]
19. GM-144, a novel lipophilic vaginal contraceptive gel-microemulsion.
D'Cruz OJ; Yiv SH; Uckun FM
AAPS PharmSciTech; 2001 Apr; 2(2):E5. PubMed ID: 14727880
[TBL] [Abstract][Full Text] [Related]
20. A novel intravaginal delivery system for itraconazole: in vitro and in vivo evaluation.
Dobaria NB; Mashru RC; Badhan AC; Thakkar AR
Curr Drug Deliv; 2009 Apr; 6(2):151-8. PubMed ID: 19450221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
